Polmacoxib is a first-in-class NSAID drug candidate that acts as a dual inhibitor of COX-2 and carbonic anhydrase (CA). It exhibits superior safety for cardiovascular, renal, and gastrointestinal tissues due to its dual COX-2 and CA binding properties. Polmacoxib inhibits premalignant and malignant colorectal lesions in mouse models, partly through inhibiting tumor cell proliferation. Source summary: Polmacoxib is a research-use small-molecule compound for biochemical studies, synthesis, and SAR research in inhibitor discovery workflows.
Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Cancer | Carbonic Anhydrase
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.
日本语
한국어
Français
Deutsch
España
Türkiye